Investments, Funding & Disinvestment

The acquisition follows Stryker’s earlier move into the vascular intervention market through its approximately US$4.9 billion purchase of Inari Medical in 2025.

The next phase will focus on installing and validating fill-and-finish equipment, strengthening quality control systems, building specialized workforce capacity, and preparing for compliant vaccine manufacturing.

Through the proposed partnership, Africa CDC and Aspen plan to establish a multi-year collaboration to boost local manufacturing capacity, improve supply security, and create sustainable markets for African-made vaccines.

CTTQ will also purchase a supply of bepirovirsen for an initial period of five and a half years, while GSK will record product sales from the arrangement, though the companies are not disclosing the financial value of the deal.

The initiative builds on PureLab’s expansive diagnostic footprint, which includes more than 145 laboratories, over 1,400 licensed clinical professionals, and more than 50 accreditations across its testing network.

The new 250,000-square-foot (23,226-square-metre) Bellwether Laboratory will significantly expand global production capacity for actinium-225 (Ac-225).

The financing consortium includes Proparco, the European Investment Bank through the Human Development Accelerator initiative, and the International Finance Corporation.

Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.

The expansion will also include upgrades to clinical infrastructure and medical equipment, enabling the hospital to deliver more integrated and specialised healthcare services while responding to rising patient demand.

The Denton facility will become Novartis’ first manufacturing site in Texas and its fifth radioligand therapy production site in the country.